Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"
Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated